ClinicalTrials.gg
RecruitingNCT07457554RQCalUpdated Nov 18, 2026

Will the Use of Respiratory Quotient ''RQ'' Improve Treatment Outcomes for Intensive Care Unit (ICU) Patients?

An interventional study of RQ guided nutrition and Standard Treatment (Guideline-Based) in Nutritional Therapy in an ICU and Critically Ill Patients Requiring Mechanical Ventilation, sponsored by Poznan University of Medical Sciences. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Poznan University of Medical Sciences · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Oct 2024, registered Feb 2026).
  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Nov 18, 2026Study documents postedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Introduction and assumptions:

Optimal nutritional therapy is an important component of intensive care. Both underfeeding and overfeeding are associated with poorer outcomes in critically ill patients. Indirect calorimetry is the gold standard for assessing resting energy expenditure (REE). It also provides the respiratory quotient (RQ), calculated as carbon dioxide production divided by oxygen consumption. RQ reflects substrate utilization and may help guide the choice of nutritional formulations. The RQCal study evaluates whether using RQ in addition to REE improves clinical outcomes in mechanically ventilated ICU patients.

Methodology:

This is a single-center, prospective, randomized controlled trial in adult ICU patients receiving invasive mechanical ventilation with an anticipated duration of more than 48 hours. Participants are allocated 1:1 to standard nutritional therapy guided by indirect calorimetry and REE, or to the same therapy with additional RQ-guided selection of nutritional formulations. In the intervention group, formulations are selected according to predefined RQ categories (\<0.80, 0.80-0.85, and >0.85). Laboratory parameters related to nutritional and metabolic status are assessed during routine care.

The primary outcome is 28-day ventilator-free days (VFD), defined as days alive and free from invasive mechanical ventilation within 28 days after randomization; patients who die before day 28 or remain invasively ventilated throughout this period receive 0 VFD. Secondary outcomes include 28-day survival, survival to ICU and hospital discharge, ICU length of stay, ventilator-associated pneumonia, illness severity scores, and laboratory parameters. The maximum planned enrollment is 240 participants (120 per group).

The primary efficacy analysis follows the intention-to-treat principle, estimating the between-group difference in mean VFD using a linear model with HC3 robust standard errors. The Mann-Whitney U test is a sensitivity analysis; a supportive analysis includes participants ventilated for more than 48 hours.

Study period: October 2024 to September 2027.

Inclusion criteria: Age 18-85 years; ICU treatment; invasive mechanical ventilation with an anticipated need for more than 48 hours; universal health insurance.

Exclusion criteria: ECMO; FiO2 >60%; no invasive mechanical ventilation; expected survival under 48 hours; pregnancy; age \<18 or >85 years; prisoners transferred from penal institutions; significant gastrointestinal disorders preventing standard nutritional therapy.

Interim analyses and discontinuation:

Two interim efficacy analyses are planned at approximately 80 and 160 randomized participants with available primary-outcome data, using a Lan-DeMets alpha-spending function approximating O'Brien-Fleming boundaries to control the overall two-sided type I error rate at 0.05. The trial may be stopped early for compelling efficacy or significant safety concerns; no formal futility stopping is planned. Individual nutritional interventions may be discontinued for intolerance or clinical reasons, but all randomized participants remain in the primary intention-to-treat analysis.

Expected results:

RQ-guided selection of nutritional formulations may improve metabolic and nutritional management and increase 28-day VFD, with potential benefits for secondary clinical outcomes. Findings may inform nutritional treatment strategies for other ICUs.

02

Conditions studied

  • Nutritional Therapy in an ICU
  • Critically Ill Patients Requiring Mechanical Ventilation

Keywords

  • intensive care unit
  • ICU
  • respiratory quotient
  • RQ
  • indirect calorimetry
  • ventilator-free days
  • VFD
03

In context

Lead sponsor

Poznan University of Medical Sciences is the lead sponsor of 152 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients treated in the ICU.
  • Invasive mechanical ventilation with an anticipated duration of more than 48 hours.
  • Covered by universal health insurance.

Exclusion criteria

Exclusion Criteria:

  • ECMO therapy.
  • Mechanical ventilation requiring FiO2 >60%.
  • Spontaneous breathing without invasive mechanical ventilation.
  • Critically ill patients not expected to survive the next 48 hours.
  • Pregnancy.
  • Age \<18 or >85 years.
  • Prisoners transferred from penal institutions.
  • Significant gastrointestinal disorders preventing standard nutritional therapy.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
240 participants (estimated)

Study arms

  • Active comparator
    Control

    Other: Standard Treatment (Guideline-Based)

  • Experimental
    Research group

    Other: RQ guided nutrition

Interventions

  • OtherRQ guided nutrition

    In the study group, nutritional preparations will be additionally systematized and selected for each patient depending on their RQ value, and caloric requirements will be controlled by indirect calorimetry and REE, as in the control group.

  • OtherStandard Treatment (Guideline-Based)

    Standard nutritional treatment according to ESPEN guidelines, guided by indirect calorimetry and REE, without using RQ for the selection of nutritional formulations.

06

What researchers measure

Primary outcomes

  1. 28-day ventilator-free days (VFD)

    Number of days alive and free from invasive mechanical ventilation during the first 28 days after randomization. A period of at least 24 consecutive hours free from invasive mechanical ventilation is required to qualify as a ventilator-free day. Participants who die before day 28 or require invasive mechanical ventilation for 28 days or longer will be assigned 0 VFD.

    Time frame: First 28 days after randomization.

Secondary outcomes

  1. 28-day survival rate

    Survival status at 28 days after randomization.

    Time frame: 28 days after randomization.

  2. Survival rate in an ICU.

    If the patient survives until discharge from an ICU after initial admission to ICU and inclusion in the study.

    Time frame: From initial admission to the ICU and inclusion in the study to discharge from the ICU, assessed up to 120 days from the randomisation.

  3. Survival rate until hospital discharge.

    If the patient survives until hospital discharge after initial admission to ICU and inclusion in the study.

    Time frame: From initial admission to ICU and inclusion in the study to hospital discharge, assessed up to 120 days from the randomisation.

  4. Length of stay in the ICU.

    Measured total length of stay in the ICU until discharge from the ICU.

    Time frame: From initial ICU admission to ICU discharge or death, assessed up to 120 days after randomization.

  5. Ventilator-associated pneumonia (VAP)

    Occurrence of VAP during ICU stay

    Time frame: From initial admission to the ICU and inclusion in the study to discharge from the ICU, monitored up to 120 days from the randomisation.

  6. Sequential Organ Failure Assessment (SOFA) score

    Measurement of Sequential Organ Failure Assessment (SOFA) score , on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study. The scale ranges from 0 to 24 points, where 0 represents the lowest predicted mortality and 24 represents the highest predicted mortality.

    Time frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.

  7. Acute Physiology and Chronic Health Evaluation II (APACHE II) score

    Measurement of Acute Physiology and Chronic Health Evaluation II (APACHE II) score , on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study. The scale ranges from 0 to 71 points, where 0 represents the lowest predicted mortality and 71 represents the highest predicted mortality.

    Time frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.

  8. Simplified Acute Physiology Score II (SAPS II)

    Measurement of Simplified Acute Physiology Score II (SAPS II) , on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study. The scale ranges from 0 to 163 points, where 0 represents the lowest predicted mortality and 163 represents the highest predicted mortality.

    Time frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.

07

Study locations

1 of 1 sites recruiting
  • University Clinical Hospital in Poznań, ul. Przybyszewskiego 49, Clinical Department of Anesthesiology, Intensive Care, and Pain Management
    Poznan, Wielkopolska 60-355, Poland
    Recruiting
    • Amadeusz Juliusz Woźniak, MD · Contactamadeusz.wozniak@ump.edu.pl · +48 61 161 3250
    • Amadeusz Juliusz Woźniak, MD · Principal investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data may be made available upon reasonable request to the corresponding author, following assessment by the study supervisors and approval by the principal investigator.

Supporting information: Study protocol

Time frame: Data will be available after completion of the study and publication of the final study results.

Access criteria: Access may be granted to qualified researchers upon reasonable request to the corresponding author, following assessment of the request by the study supervisors and approval by the principal investigator.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2027 → Dec 2027, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Mar 9, 2026
StartActual
Oct 1, 2024
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2027was Oct 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Oct 31, 2027→Dec 31, 2027
Nov 18, 2026
Enrollment
236→240
Nov 18, 2026
Eligibility
1 inclusion criterion edited, 1 added, 1 removed; 3 exclusion criteria edited, 4 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedpatientPatients treated in the ICU.
  • Removedmechanically ventilated
  • AddedInvasive mechanical ventilation with an anticipated duration of more than 48 hours.
Exclusion criteria
  • EditedmechanicalMechanical ventilation with an oxygen concentration in the breathing mixturerequiring FiO2 > 60%.
  • ChangedBefore breathing independently without the aid of a ventilatorNow Spontaneous breathing without invasive mechanical ventilation.
  • EditedcriticallyCritically ill patients who are not expected to survive the next 48 hours.
  • Removedpregnant women
  • AddedPregnancy.
  • AddedAge <18 or >85 years.
  • AddedPrisoners transferred from penal institutions.
  • AddedSignificant gastrointestinal disorders preventing standard nutritional therapy.
Nov 18, 2026
Interventions
Added RQ guided nutrition·Standard Treatment (Guideline-Based); removed Dietary supplement: RQ guided nutrition·Dietary supplement: Standard Treatment (Guideline-Based)
Nov 18, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • Description28-day ventilator-free days (VFD): how it is measured was reworded
Nov 18, 2026
Documents
Nov 18, 2026
Secondary outcomes
1 time frame changed, 3 added, 3 removed, 2 description edited
What changed in the outcomes
  • AddedSequential Organ Failure Assessment (SOFA) scoreTime frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
  • AddedAcute Physiology and Chronic Health Evaluation II (APACHE II) scoreTime frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
  • AddedSimplified Acute Physiology Score II (SAPS II)Time frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
  • Time frameLength of stay in the ICU.From initial admission to the ICU and inclusion in the study to discharge from the hospital or death, assessed up to 120 days from the randomisation. → From initial ICU admission to ICU discharge or death, assessed up to 120 days after randomization.
  • DescriptionSurvival rate in an ICU.: how it is measured was reworded
  • DescriptionSurvival rate until hospital discharge.: how it is measured was reworded
  • Removedother outcomeSequential Organ Failure Assessment (SOFA) scoreTime frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
  • Removedother outcomeAcute Physiology and Chronic Health Evaluation II (APACHE II) scoreTime frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
  • Removedother outcomeSimplified Acute Physiology Score II (SAPS II)Time frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Documents Study protocol ↗ updated
    Study completion Oct 31, 2027→Dec 31, 2027
    Enrollment 236→240
    Eligibility 1 inclusion criterion edited, 1 added, 1 removed; 3 exclusion criteria edited, 4 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedpatientPatients treated in the ICU.
    • Removedmechanically ventilated
    • AddedInvasive mechanical ventilation with an anticipated duration of more than 48 hours.
    Exclusion criteria
    • EditedmechanicalMechanical ventilation with an oxygen concentration in the breathing mixturerequiring FiO2 > 60%.
    • ChangedBefore breathing independently without the aid of a ventilatorNow Spontaneous breathing without invasive mechanical ventilation.
    • EditedcriticallyCritically ill patients who are not expected to survive the next 48 hours.
    • Removedpregnant women
    • AddedPregnancy.
    • AddedAge <18 or >85 years.
    • AddedPrisoners transferred from penal institutions.
    • AddedSignificant gastrointestinal disorders preventing standard nutritional therapy.
    Primary outcomes 1 description edited
    What changed in the outcomes
    • Description28-day ventilator-free days (VFD): how it is measured was reworded
    Secondary outcomes 1 time frame changed, 3 added, 3 removed, 2 description edited
    What changed in the outcomes
    • AddedSequential Organ Failure Assessment (SOFA) scoreTime frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
    • AddedAcute Physiology and Chronic Health Evaluation II (APACHE II) scoreTime frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
    • AddedSimplified Acute Physiology Score II (SAPS II)Time frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
    • Time frameLength of stay in the ICU.From initial admission to the ICU and inclusion in the study to discharge from the hospital or death, assessed up to 120 days from the randomisation. → From initial ICU admission to ICU discharge or death, assessed up to 120 days after randomization.
    • DescriptionSurvival rate in an ICU.: how it is measured was reworded
    • DescriptionSurvival rate until hospital discharge.: how it is measured was reworded
    • Removedother outcomeSequential Organ Failure Assessment (SOFA) scoreTime frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
    • Removedother outcomeAcute Physiology and Chronic Health Evaluation II (APACHE II) scoreTime frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
    • Removedother outcomeSimplified Acute Physiology Score II (SAPS II)Time frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
    Interventions Added RQ guided nutrition·Standard Treatment (Guideline-Based); removed Dietary supplement: RQ guided nutrition·Dietary supplement: Standard Treatment (Guideline-Based)
    + 3 other changes: verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07457554
Responsible party
ek. Woźniak Amadeusz (MD, specialty Anesthesiology and Intensive Care, Poznan University of Medical Sciences) — Principal investigator
First posted
Mar 9, 2026
Start date
Oct 1, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Amadeusz Juliusz Woźniak, MD
Contact
amadeusz.wozniak@ump.edu.pl
+48 603 927 222
University Clinical Hospital in Poznań
Contact
anestezjologiap@usk.poznan.pl
+48 61 161 3250
Zbigniew Żaba, PhD
study director · University Clinical Hospital in Poznań, ul. Przybyszewskiego 49, Clinical Department of Anesthesiology, Intensive Care, and Pain Management Departments of Emergency Medicine,
Amadeusz Juliusz Woźniak, MD
principal investigator · University Clinical Hospital in Poznań, ul. Przybyszewskiego 49, Clinical Department of Anesthesiology, Intensive Care, and Pain Management

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion